Zero tolerance for acronyms Colin B Begg In the course of my spell as Editor of this journal, many things that I was only vaguely aware of have become much more apparent. Perhaps the most notable of these is awareness of the epidemic in modern writing style to define and use acronyms compulsively, what one might call compulsive use of acronyms (CUA), or to give it its more formal title, acronym diarrhea disorder (ADD). I've wondered if the scale of this trend in this journal specifically is promoted by the fact that clinical trialists have been wedded to acronyms for a long time, by virtue of the fact that it has become de rigeur to anoint individual clinical trials with names, such as SPRINT, STRIDE, TODAY, IMPROVE, RECRUIT and so forth. However, in preparing for this article, I did what all self-respecting scientists would do when describing a phenomenon. I performed a literature search (in Google) finding, reassuringly, articles with titles like ''It's Death by Acronym'' (http://www.smh.com.au/ small-business/managing/work-in-progress/its-deathby-acronym-20141009-3ho8g.html), confirming that there are others out there who are as dismayed by this trend as I am.
It is commonplace for me to confront article submissions in which the definition of acronyms begins immediately, often at the very beginning of the abstract, and continues unabated, to the point where the author seems to feel the need to create a new acronym every time any phrase or term is used more than once. For those of you who are caught up in this epidemic, consciously or unconsciously, please stop for a moment and consider the impact that acronyms have on the readability of your work. Our ultimate goal in presenting our work in print is, after all, to engage the reader's interest and to convey our messages clearly. How is this possible if the reader is continually confronting acronyms, few of which are familiar? It is exceptionally annoying to have to continually leaf back through the article for a reminder of what CUA represents, for example. Often, in these cases, the acronyms will flow one after the other in a single sentence, leaving the reader completely bewildered and increasingly frustrated.
For some time now we have had a policy on acronyms at this journal, although it is apparent that few authors who submit articles are paying any attention. This policy is posted on the website amid the author instructions at https://us.sagepub.com/en-us/nam/jour nal/clinical-trials#submission-guidelines where it is stated that ''acronyms are strongly discouraged except for those that will be recognizable to all readers without explanation,'' although in applying this policy in practice we have elected to allow an exception whereby the author can define a single key acronym that is used many times throughout the manuscript that does not meet this standard. What acronyms do meet the standard? The answer-very few. I will concede that a term such as DNA will be recognizable and possibly does not even require a definition. Also, terms such as FDA, NIH and IRB are frequently used by authors in our field and will, I think, be familiar and recognized by virtually all readers of Clinical Trials. However, each of these three terms is USA-centric, with completely different acronyms for corresponding entities in other countries, and this is an international journal. Nonetheless, we have consistently permitted these, in part because they are so familiar that people even use the terms in their abbreviated form in common speech. As we move further from this level of familiarity, things become much less clear-cut. In articles addressing methodology for analyzing randomized clinical trials (RCT), I have often encountered acronyms such as ITT (intention to treat), CRT (cluster randomized trial), CR (complete response) and a host of others. Are these terms ''recognizable to all readers without explanation''? I don't think so. They may be recognizable to aficionados and specialists interested in particular topics, but not to the general readership of the journal. Moreover, liberal use of acronyms such as these tends to encourage authors to use additional acronyms further down the recognition scale, such as PP (per protocol), AT (as treated), OS (overall survival), RR (response rate) and so on. Before long, writers of such articles will have descended to using a sentence like the following: ''There is less bias when using ITT versus PP or AT when using CR as an endpoint as opposed to OS.'' To many readers, this kind of sentence is gibberish.
At the editorial office, we have been trying to beat back this trend, but the pro bono nature of our efforts as editors limits the amount of time we can put into policing the quality of the writing. I'm sure many of you may have been surprised to see numerous acronyms bleed into some of our published papers despite the fact that we may have been stricter with your own submission. I assure you that we are trying our best to be fair and consistent. It will help greatly if acronyms are culled by those of you submitting articles prior to submission, as required by our authorship guidelines, rather than relying on a more challenging post hoc pruning, late in the editorial process.
Ultimately, the goal here is to encourage the production of articles that convey their messages clearly, and to do so in a way that encourages the broad disciplinary readership of our journal to actually read broadly. The facilitation of inter-disciplinary communication goes way beyond acronyms to include problems associated with overuse of technical jargon generally, and tackling this is far beyond our mandate at the journal. However, curtailing the use of acronyms represents something we can actually accomplish, if only locally. As a result, I am announcing henceforth our ZeTA policy-Zero Tolerance for Acronyms. Please be aware of this if you are contemplating a submission.
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